The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of dose intensity of XELOX and MFOLFOX6 on survival of metastatic colorectal cancer patients: A retrospective analysis at the Jewish General Hospital between 2006 and 2013.
Aline Mamo
No relevant relationships to disclose
Tomas Kavan
No relevant relationships to disclose
Young Soo Rho
No relevant relationships to disclose
Gerald Batist
No relevant relationships to disclose
Petr Kavan
No relevant relationships to disclose